NBIX
Neurocrine Biosciences, Inc.
Price Chart
Latest Quote
$161.44
-0.18 (-0.11%)
Current Price
| Previous Close | $161.62 |
| Open | $161.62 |
| Day High | $163.53 |
| Day Low | $160.44 |
| Volume | 877,264 |
Stock Information
| Shares Outstanding | 100.55M |
| Total Debt | $463.50M |
| Cash Equivalents | $1.32B |
| Revenue | $3.10B |
| Net Income | $668.60M |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Market Cap | $16.23B |
| P/E Ratio | 24.80 |
| EPS (TTM) | $6.51 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $15.38B |
| Sales | $3.10B |
| Income | $668.60M |
| Book/sh | $33.87 |
| Cash/sh | $13.09 |
| Employees | 2K |
Financial Ratios
| Quick Ratio | 2.51 |
| Current Ratio | 2.93 |
| Debt/Eq | 13.60 |
| EPS Growth TTM | 2405.10% |
Returns & Margins
| ROA | 11.62% |
| ROE | 22.50% |
| Gross Margin | 64.37% |
| Operating Margin | 22.84% |
| Profit Margin | 21.55% |
Ownership
| Insider Ownership | 1.08% |
| Institutional Ownership | 103.91% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | 12.74 |
| PEG | 0.46 |
| P/S | 5.23 |
| P/B | 4.77 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $194.38 |
Technical Indicators
| SMA20 | $160.32 |
| SMA50 | $148.80 |
| SMA200 | $141.52 |
| RSI | 58.64 |
| ATR | 5.1350 |
| Shares Float | 99.29M |
| Short Float | 7.16% |
| Short Ratio | 4.28 |
| Volatility | 0.40 |
| Rel Volume | 0.89 |
Performance History
| Week | +1.21% |
| Month | +3.82% |
| Quarter | +27.07% |
| 6 Months | +13.82% |
| YTD | +14.82% |
| Year | +27.57% |
| 3 Years | +66.69% |
| 5 Years | +64.92% |
| 10 Years | +273.01% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-23 | $161.44 | 1,076,100 |
| 2026-06-22 | $161.62 | 1,008,800 |
| 2026-06-18 | $158.29 | 2,718,000 |
| 2026-06-17 | $159.00 | 1,037,700 |
| 2026-06-16 | $156.42 | 934,400 |
| 2026-06-15 | $159.51 | 1,243,600 |
| 2026-06-12 | $159.76 | 1,055,100 |
| 2026-06-11 | $162.71 | 764,800 |
| 2026-06-10 | $160.86 | 1,097,200 |
| 2026-06-09 | $165.24 | 1,098,800 |
| 2026-06-08 | $163.12 | 804,500 |
| 2026-06-05 | $163.88 | 1,050,100 |
| 2026-06-04 | $167.35 | 1,301,800 |
| 2026-06-03 | $165.11 | 1,941,700 |
| 2026-06-02 | $154.84 | 1,039,500 |
| 2026-06-01 | $161.00 | 1,220,700 |
| 2026-05-29 | $158.30 | 1,907,800 |
| 2026-05-28 | $156.39 | 1,068,300 |
| 2026-05-27 | $155.83 | 708,600 |
| 2026-05-26 | $155.73 | 984,300 |
About Neurocrine Biosciences, Inc.
Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia, as well as offers products under the name of ALKINDI and Efmody. Its product candidates in clinical development includes NBI-1076986 to treat movement disorders; Osavampator for inadequate response to treatment in major depressive disorder; NBI-1117568 for the treatment of schizophrenia and bipolar mania; NBI-1117567 for the treatment of Alzheimer's disease; NBI 921355 for the treatment of epilepsy; NBIP-01435 for the treatment of congenital adrenal hyperplasia; NBIP-2118 for the treatment of obesity and related metabolic diseases; and NBI-1070770 to treat major depressive disorder; and NBI-1117570, NBI-1117567, NBI-1117569, NBI-1140675, and NBI-1065890 for neuropsychiatric and neurological conditions. The company also has license and collaboration agreements with Nxera Pharma UK Limited; Takeda Pharmaceutical Company Limited; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; Sanofi S.A.; Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.
đ° Latest News
Is Neurocrine Biosciences, Inc. (NBIX) A Good Stock To Buy Now?
Insider Monkey âĸ 2026-06-15T14:55:27Z
Assessing Neurocrine Biosciences (NBIX) Valuation After Recent Share Price Momentum
Simply Wall St. âĸ 2026-06-05T04:50:58Z
RBC Capital Raises its Price Target on Neurocrine Biosciences (NBIX)
Insider Monkey âĸ 2026-06-04T16:49:53Z
Dow Jones Futures Rise, But Broadcom, CrowdStrike, Ciena Hit Techs; SpaceX IPO Price Target Set
Investor's Business Daily âĸ 2026-06-04T12:06:22Z
Meta Platforms upgraded, Okta downgraded: Wall Street's top analyst calls
The Fly âĸ 2026-06-02T13:43:12Z
Centene, Deckers and 14 Other âDividend Hopefulsâ
Barrons.com âĸ 2026-06-02T05:30:00Z
Neurocrine Biosciences Should See More Upside on Crenessity Growth, RBC Says
MT Newswires âĸ 2026-05-29T16:21:04ZUS High Growth Tech Stocks To Watch Now
Simply Wall St. âĸ 2026-05-26T11:38:35Z
Bernstein Initiates Coverage of Neurocrine Biosciences (NBIX) with Outperform
Insider Monkey âĸ 2026-05-25T23:49:01Z
Will New Real-World INGREZZA (valbenazine) Data in Mild TD Change Neurocrine Biosciences' (NBIX) Narrative
Simply Wall St. âĸ 2026-05-21T08:10:42Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $52,100,000 | $34,000,000 | $39,700,000 | $23,200,000 |
| Cost Of Revenue | $52,100,000 | $34,000,000 | $39,700,000 | $23,200,000 |
| Total Revenue | $2,860,500,000 | $2,355,300,000 | $1,887,100,000 | $1,488,700,000 |
| Operating Revenue | $2,860,500,000 | $2,355,300,000 | $1,887,100,000 | $1,488,700,000 |
| Expenses | ||||
| Total Expenses | $2,224,000,000 | $1,772,300,000 | $1,492,300,000 | $1,239,700,000 |
| Other Income Expense | $-21,400,000 | $-61,400,000 | $-115,500,000 | $-39,200,000 |
| Net Non Operating Interest Income Expense | $90,300,000 | $-35,600,000 | $52,800,000 | $4,100,000 |
| Operating Expense | $2,171,900,000 | $1,738,300,000 | $1,452,600,000 | $1,216,500,000 |
| Interest Expense | - | $126,600,000 | $4,600,000 | $7,100,000 |
| Interest Expense Non Operating | - | $126,600,000 | $4,600,000 | $7,100,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $478,600,000 | $341,300,000 | $249,700,000 | $154,500,000 |
| Net Interest Income | $90,300,000 | $-35,600,000 | $52,800,000 | $4,100,000 |
| Interest Income | $90,300,000 | $91,000,000 | $52,800,000 | $4,100,000 |
| Normalized Income | $493,119,478 | $384,418,971 | $336,542,367 | $182,814,165 |
| Net Income From Continuing And Discontinued Operation | $478,600,000 | $341,300,000 | $249,700,000 | $154,500,000 |
| Total Operating Income As Reported | $619,100,000 | $570,500,000 | $250,900,000 | $249,000,000 |
| Net Income Common Stockholders | $478,600,000 | $341,300,000 | $249,700,000 | $154,500,000 |
| Net Income | $478,600,000 | $341,300,000 | $249,700,000 | $154,500,000 |
| Net Income Including Noncontrolling Interests | $478,600,000 | $341,300,000 | $249,700,000 | $154,500,000 |
| Net Income Continuous Operations | $478,600,000 | $341,300,000 | $249,700,000 | $154,500,000 |
| Pretax Income | $705,400,000 | $486,000,000 | $332,100,000 | $213,900,000 |
| Special Income Charges | $-17,400,000 | $-14,700,000 | $-143,900,000 | $-70,000,000 |
| Interest Income Non Operating | $90,300,000 | $91,000,000 | $52,800,000 | $4,100,000 |
| Operating Income | $636,500,000 | $583,000,000 | $394,800,000 | $249,000,000 |
| Gross Profit | $2,808,400,000 | $2,321,300,000 | $1,847,400,000 | $1,465,500,000 |
| Per Share | ||||
| Diluted EPS | $4.67 | $3.29 | $2.47 | $1.56 |
| Basic EPS | $4.81 | $3.40 | $2.56 | $1.61 |
| Other | ||||
| Tax Effect Of Unusual Items | $-6,880,522 | $-18,281,029 | $-28,657,633 | $-10,885,835 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $688,000,000 | $701,100,000 | $531,600,000 | $303,800,000 |
| Total Unusual Items | $-21,400,000 | $-61,400,000 | $-115,500,000 | $-39,200,000 |
| Total Unusual Items Excluding Goodwill | $-21,400,000 | $-61,400,000 | $-115,500,000 | $-39,200,000 |
| Reconciled Depreciation | $30,100,000 | $27,100,000 | $21,300,000 | $15,600,000 |
| EBITDA (Bullshit earnings) | $666,600,000 | $639,700,000 | $416,100,000 | $264,600,000 |
| EBIT | $636,500,000 | $612,600,000 | $394,800,000 | $249,000,000 |
| Diluted Average Shares | $102,500,000 | $103,700,000 | $101,000,000 | $98,900,000 |
| Basic Average Shares | $99,500,000 | $100,400,000 | $97,700,000 | $95,800,000 |
| Diluted NI Availto Com Stockholders | $478,600,000 | $341,300,000 | $249,700,000 | $154,500,000 |
| Tax Provision | $226,800,000 | $144,700,000 | $82,400,000 | $59,400,000 |
| Other Special Charges | $17,400,000 | $14,700,000 | $143,900,000 | $70,000,000 |
| Gain On Sale Of Security | $-4,000,000 | $-46,700,000 | $28,400,000 | $30,800,000 |
| Research And Development | $1,015,700,000 | $731,100,000 | $565,000,000 | $463,800,000 |
| Selling General And Administration | $1,156,200,000 | $1,007,200,000 | $887,600,000 | $752,700,000 |
Fetched: 2026-06-14
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $3,253,100,000 | $2,589,700,000 | $2,196,500,000 | $1,670,600,000 |
| Total Assets | $4,631,500,000 | $3,718,700,000 | $3,251,400,000 | $2,368,700,000 |
| Total Non Current Assets | $2,108,800,000 | $1,994,000,000 | $1,644,400,000 | $915,200,000 |
| Other Non Current Assets | $59,500,000 | $52,000,000 | $49,600,000 | $25,000,000 |
| Non Current Deferred Assets | $320,300,000 | $485,700,000 | $362,600,000 | $305,900,000 |
| Non Current Deferred Taxes Assets | $320,300,000 | $485,700,000 | $362,600,000 | $305,900,000 |
| Investmentin Financial Assets | $1,183,800,000 | $864,300,000 | $849,400,000 | $401,500,000 |
| Current Assets | $2,522,700,000 | $1,724,700,000 | $1,607,000,000 | $1,453,500,000 |
| Other Current Assets | $115,800,000 | $63,600,000 | $97,800,000 | $79,100,000 |
| Prepaid Assets | $170,700,000 | $48,500,000 | - | - |
| Inventory | $69,000,000 | $57,400,000 | $38,300,000 | $35,100,000 |
| Receivables | $686,800,000 | $479,100,000 | $439,300,000 | $350,000,000 |
| Accounts Receivable | $686,800,000 | $479,100,000 | $439,300,000 | $350,000,000 |
| Cash Cash Equivalents And Short Term Investments | $1,480,400,000 | $1,076,100,000 | $1,031,600,000 | $989,300,000 |
| Cash And Cash Equivalents | $713,000,000 | $233,000,000 | $251,100,000 | $262,900,000 |
| Goodwill And Other Intangible Assets | - | $36,500,000 | $35,500,000 | $37,200,000 |
| Other Intangible Assets | - | $36,500,000 | $35,500,000 | $37,200,000 |
| Debt | ||||
| Total Debt | $415,300,000 | $455,100,000 | $428,400,000 | $262,900,000 |
| Long Term Debt And Capital Lease Obligation | $415,300,000 | $455,100,000 | $258,300,000 | $93,500,000 |
| Current Debt And Capital Lease Obligation | - | - | $170,100,000 | $169,400,000 |
| Current Debt | - | - | $170,100,000 | $169,400,000 |
| Other Current Borrowings | - | - | $170,100,000 | $169,400,000 |
| Long Term Debt | - | - | - | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $1,378,400,000 | $1,129,000,000 | $1,019,400,000 | $660,900,000 |
| Total Non Current Liabilities Net Minority Interest | $635,000,000 | $621,300,000 | $364,600,000 | $123,200,000 |
| Other Non Current Liabilities | $5,200,000 | $5,500,000 | $10,300,000 | $9,900,000 |
| Tradeand Other Payables Non Current | $214,500,000 | $160,700,000 | $96,000,000 | $19,800,000 |
| Current Liabilities | $743,400,000 | $507,700,000 | $654,800,000 | $537,700,000 |
| Other Current Liabilities | $69,100,000 | $46,100,000 | $35,900,000 | $20,700,000 |
| Payables And Accrued Expenses | $319,500,000 | $209,900,000 | $223,300,000 | $142,900,000 |
| Payables | $172,900,000 | $109,900,000 | $133,300,000 | $76,300,000 |
| Total Tax Payable | $68,000,000 | $10,000,000 | $24,400,000 | $9,000,000 |
| Income Tax Payable | $68,000,000 | $10,000,000 | $24,400,000 | $9,000,000 |
| Accounts Payable | $104,900,000 | $99,900,000 | $133,300,000 | $67,300,000 |
| Equity | ||||
| Common Stock Equity | $3,253,100,000 | $2,589,700,000 | $2,232,000,000 | $1,707,800,000 |
| Total Equity Gross Minority Interest | $3,253,100,000 | $2,589,700,000 | $2,232,000,000 | $1,707,800,000 |
| Stockholders Equity | $3,253,100,000 | $2,589,700,000 | $2,232,000,000 | $1,707,800,000 |
| Gains Losses Not Affecting Retained Earnings | $13,100,000 | $5,800,000 | $7,000,000 | $-7,900,000 |
| Other Equity Adjustments | $13,100,000 | $5,800,000 | $7,000,000 | $-7,900,000 |
| Retained Earnings | $447,700,000 | $29,200,000 | $-157,100,000 | $-406,800,000 |
| Other | ||||
| Ordinary Shares Number | $100,100,000 | $99,400,000 | $98,700,000 | $96,500,000 |
| Share Issued | $100,100,000 | $99,400,000 | $98,700,000 | $96,500,000 |
| Tangible Book Value | $3,253,100,000 | $2,589,700,000 | $2,196,500,000 | $1,670,600,000 |
| Invested Capital | $3,253,100,000 | $2,589,700,000 | $2,402,100,000 | $1,877,200,000 |
| Working Capital | $1,779,300,000 | $1,217,000,000 | $952,200,000 | $915,800,000 |
| Capital Lease Obligations | $415,300,000 | $455,100,000 | $258,300,000 | $93,500,000 |
| Total Capitalization | $3,253,100,000 | $2,589,700,000 | $2,232,000,000 | $1,707,800,000 |
| Additional Paid In Capital | $2,792,200,000 | $2,554,600,000 | $2,382,000,000 | $2,122,400,000 |
| Capital Stock | $100,000 | $100,000 | $100,000 | $100,000 |
| Common Stock | $100,000 | $100,000 | $100,000 | $100,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $415,300,000 | $455,100,000 | $258,300,000 | $93,500,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $128,800,000 | $107,500,000 | $86,200,000 | $72,800,000 |
| Current Provisions | $226,000,000 | $144,200,000 | $139,300,000 | $131,900,000 |
| Current Accrued Expenses | $146,600,000 | $100,000,000 | $90,000,000 | $66,600,000 |
| Investments And Advances | $1,183,800,000 | $864,300,000 | $849,400,000 | $401,500,000 |
| Available For Sale Securities | $1,183,800,000 | $864,300,000 | $849,400,000 | $401,500,000 |
| Net PPE | $545,200,000 | $592,000,000 | $347,300,000 | $145,600,000 |
| Accumulated Depreciation | $-118,300,000 | $-106,500,000 | $-83,000,000 | $-66,300,000 |
| Gross PPE | $663,500,000 | $698,500,000 | $430,300,000 | $211,900,000 |
| Leases | $35,600,000 | $35,900,000 | $38,100,000 | $37,900,000 |
| Other Properties | $578,700,000 | $605,100,000 | $356,100,000 | $145,800,000 |
| Machinery Furniture Equipment | $49,200,000 | $57,500,000 | $36,100,000 | $28,200,000 |
| Properties | $0 | $0 | $0 | $0 |
| Inventories Adjustments Allowances | $-200,000 | $0 | $-5,200,000 | $0 |
| Finished Goods | $14,300,000 | $12,800,000 | $12,300,000 | $17,500,000 |
| Work In Process | $19,200,000 | $10,900,000 | $9,700,000 | $5,600,000 |
| Raw Materials | $35,700,000 | $33,700,000 | $21,500,000 | $12,000,000 |
| Other Short Term Investments | $767,400,000 | $843,100,000 | $780,500,000 | $726,400,000 |
Fetched: 2026-06-14
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $748,700,000 | $557,200,000 | $361,600,000 | $322,900,000 |
| Operating Activities | ||||
| Operating Cash Flow | $782,700,000 | $595,400,000 | $389,900,000 | $339,400,000 |
| Cash Flow From Continuing Operating Activities | $782,700,000 | $595,400,000 | $389,900,000 | $339,400,000 |
| Operating Gains Losses | - | - | - | $70,000,000 |
| Investing Activities | ||||
| Capital Expenditure | $-34,000,000 | $-38,200,000 | $-28,300,000 | $-16,500,000 |
| Investing Cash Flow | $-264,400,000 | $-126,800,000 | $-467,100,000 | $-177,100,000 |
| Cash Flow From Continuing Investing Activities | $-264,400,000 | $-126,800,000 | $-467,100,000 | $-177,100,000 |
| Capital Expenditure Reported | $-34,000,000 | $-38,200,000 | $-28,300,000 | $-16,500,000 |
| Financing Activities | ||||
| Repurchase Of Capital Stock | $-167,700,000 | $-300,000,000 | $0 | $0 |
| Financing Cash Flow | $-38,300,000 | $-486,700,000 | $65,300,000 | $-234,300,000 |
| Cash Flow From Continuing Financing Activities | $-38,300,000 | $-486,700,000 | $65,300,000 | $-234,300,000 |
| Net Common Stock Issuance | $-167,700,000 | $-300,000,000 | $0 | $0 |
| Other | ||||
| Repayment Of Debt | $0 | $-308,800,000 | $0 | $-279,000,000 |
| Interest Paid Supplemental Data | $0 | $1,600,000 | $3,800,000 | $6,600,000 |
| Income Tax Paid Supplemental Data | $81,400,000 | $217,500,000 | $51,500,000 | $14,400,000 |
| End Cash Position | $721,000,000 | $241,000,000 | $259,100,000 | $270,700,000 |
| Beginning Cash Position | $241,000,000 | $259,100,000 | $270,700,000 | $344,000,000 |
| Effect Of Exchange Rate Changes | $0 | $0 | $300,000 | $-1,300,000 |
| Changes In Cash | $480,000,000 | $-18,100,000 | $-11,900,000 | $-72,000,000 |
| Proceeds From Stock Option Exercised | $129,400,000 | $122,100,000 | $65,300,000 | $44,700,000 |
| Common Stock Payments | $-167,700,000 | $-300,000,000 | $0 | $0 |
| Net Issuance Payments Of Debt | $0 | $-308,800,000 | $0 | $-279,000,000 |
| Net Long Term Debt Issuance | $0 | $-308,800,000 | $0 | $-279,000,000 |
| Long Term Debt Payments | $0 | $-308,800,000 | $0 | $-279,000,000 |
| Net Investment Purchase And Sale | $-230,400,000 | $-88,600,000 | $-438,800,000 | $-117,900,000 |
| Sale Of Investment | $1,089,400,000 | $967,500,000 | $972,400,000 | $511,000,000 |
| Purchase Of Investment | $-1,319,800,000 | $-1,056,100,000 | $-1,411,200,000 | $-628,900,000 |
| Change In Working Capital | $-128,800,000 | $-19,200,000 | $28,200,000 | $-67,400,000 |
| Change In Other Working Capital | $-63,200,000 | $-3,700,000 | $63,100,000 | $-17,200,000 |
| Change In Payables And Accrued Expense | $160,200,000 | $43,400,000 | $49,000,000 | $114,600,000 |
| Change In Inventory | $-15,300,000 | $-19,100,000 | $5,400,000 | $-2,600,000 |
| Change In Receivables | $-210,500,000 | $-39,800,000 | $-89,300,000 | $-162,200,000 |
| Changes In Account Receivables | $-210,500,000 | $-39,800,000 | $-89,300,000 | $-162,200,000 |
| Other Non Cash Items | $14,800,000 | $122,700,000 | $-18,500,000 | $71,600,000 |
| Stock Based Compensation | $217,900,000 | $195,500,000 | $194,300,000 | $173,100,000 |
| Unrealized Gain Loss On Investment Securities | $4,000,000 | $37,100,000 | $-28,400,000 | $-30,800,000 |
| Asset Impairment Charge | $700,000 | $14,000,000 | $0 | - |
| Deferred Tax | $165,400,000 | $-123,100,000 | $-56,700,000 | $19,100,000 |
| Deferred Income Tax | $165,400,000 | $-123,100,000 | $-56,700,000 | $19,100,000 |
| Depreciation Amortization Depletion | $30,100,000 | $27,100,000 | $21,300,000 | $15,600,000 |
| Depreciation And Amortization | $30,100,000 | $27,100,000 | $21,300,000 | $15,600,000 |
| Amortization Cash Flow | $4,100,000 | $3,600,000 | $3,500,000 | $500,000 |
| Amortization Of Intangibles | $4,100,000 | $3,600,000 | $3,500,000 | $500,000 |
| Depreciation | $26,000,000 | $23,500,000 | $17,800,000 | $15,100,000 |
| Net Income From Continuing Operations | $478,600,000 | $341,300,000 | $249,700,000 | $154,500,000 |
| Net Short Term Debt Issuance | - | $-308,800,000 | $0 | $-279,000,000 |
| Short Term Debt Payments | - | $-308,800,000 | $0 | $-279,000,000 |
| Net Business Purchase And Sale | - | $0 | $0 | $-42,700,000 |
| Purchase Of Business | - | $0 | $0 | $-42,700,000 |
| Amortization Of Securities | - | $-26,200,000 | $-18,300,000 | $3,700,000 |
| Net PPE Purchase And Sale | - | - | - | - |
| Purchase Of PPE | - | - | - | - |
Fetched: 2026-06-14